In 2029, the out-of-hospital market will reach 160 million yuan, but the "card slot" of pharmaceutical companies is not easy

【Pharmaceutical Network Market Analysis】The out-of-hospital market, that is, different from public medical institutions, includes online and offline pharmaceutical retail and private medical institutions
.
In the past, the in-hospital market was much larger than the out-of-hospital market, but in recent years, with the normalization of centralized procurement and the impact of the epidemic, the in-hospital market has been greatly impacted, and under the background of accelerated prescription outflow, the market pattern and commercial industry chain of the pharmaceutical industry have been gradually broken, and the scale of the out-of-hospital market has gradually expanded
.
According to Frost & Sullivan, the scale of China's out-of-hospital pharmaceutical circulation market is expected to increase from 552.
2 billion yuan in 2021 to 926.
3 billion yuan in 2026.

According to Minai.
com, by 2029, the total out-of-hospital market will reach 1.
6 trillion yuan, equaling or even surpassing the in-hospital market
.
The considerable out-of-hospital market is becoming a new position for pharmaceutical companies to compete for, and many pharmaceutical companies are vying for layout
.
Many of these multinational pharmaceutical companies have tasted the "sweetness" and are continuing to increase their investment
in out-of-hospital sales expenses.
For example, Pfizer's Luoxixi and Lipitor are both "4+7" unselected drugs purchased in quantity, and Pfizer increased its sales in the out-of-hospital market after losing the standard, so that the sales share of Luoxixi and Lipitor in the same generic name market did not decrease but increased, and the market share from 2018 to 2020 was greatly increased
.
However, what needs to be seen is that although the out-of-hospital market is large, it is not easy
for pharmaceutical companies to "gnaw down".
The industry pointed out that because the out-of-hospital market is different from the high concentration of the in-hospital market, it presents the characteristics of multi-faceted and decentralized, so pharmaceutical companies will face the challenge
of huge promotion costs and very low output.
How to explore a cheaper and more efficient out-of-hospital market model has become an urgent problem
for pharmaceutical companies.
Among them, digitalization can be described as a "good medicine"
.
At present, many pharmaceutical companies have sought to cooperate with some emerging industry platforms to jointly explore the out-of-hospital market
.
In recent years, not only multinational pharmaceutical companies, including Guangzhou Medicine Baiyunshan, Harbin Pharmaceutical, Xi'an Janssen, Yiling, Buchang, Jiangsu Wanbang, Besunyen and other local pharmaceutical companies have successively cooperated
with emerging industry platforms.
For example, Alibaba Health has built a medical and health service system
based on "cloud infrastructure", "cloud pharmacy" as the core, and "cloud hospital" as the engine based on massive patients and using digital capabilities.
On September 15, Alibaba Health released its digital patient management model to the industry for the first time, and it is reported that this innovative service solution has attracted the attention of multinational pharmaceutical companies including Merck, and more than 20 pharmaceutical companies have participated in the co-construction of this model
.
In 2020, Baiyunshan cooperated with the pharmacist gang, a large-scale digital comprehensive service platform for the domestic out-of-hospital pharmaceutical industry, on Banlangen, preparing 3 million products in advance, which were sold out
in 5 minutes after going online in the early morning.
In November 2020, several pharmaceutical companies were welcomed to the special live broadcast room of Pharmacist Bang, including Yiling, Besunyen, Baiyunshan, Biostime, Jiangsu Haosen, Panlong Yunhai, Harbin Pharmaceutical, etc
.
It is reported that previously, Pharmacist Bang had also reached strategic cooperation with multinational pharmaceutical companies such as Dongea Ejiao and Bayer and local pharmaceutical companies, and had reached cooperation
with more than a dozen pharmaceutical companies.
.
.
.
.
.
.
In general, in the past, pharmaceutical companies often laid out the out-of-hospital market after the layout of the hospital market, but now they may need to pay more attention to the development model of combining the out-of-hospital market and the online market, and start the layout of the whole life cycle of drugs earlier, in order to solve the core pain points of prescription drug retail and help the industry develop vigorously and
healthily.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.